Clinical Trial Update: RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. [Phase 1]

View source ↗

Summary

The Phase 1 feasibility trial (RENEW) evaluating CMV RNA-pulsed dendritic cell vaccines for newly diagnosed glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CMV RNA-pulsed dendritic cell vaccine

Snippet

Sponsor: University of Florida | Conditions: Glioblastoma | Phase 1 | Status: TERMINATED